0000000000756751

AUTHOR

E. Fournier

showing 4 related works from this author

Reasons for low cervical cancer survival in new accession European Union countries: a EUROCARE-5 study.

2019

Purpose: With better access to early diagnosis and appropriate treatment, cervical cancer (CC) burden decreased in several European countries. In Eastern European (EE) countries, which accessed European Union in 2004, CC survival was worse than in the rest of Europe. The present study investigates CC survival differences across five European regions, considering stage at diagnosis (local, regional and metastatic), morphology (mainly squamous versus glandular tumours) and patients’ age. Methods: We analysed 101,714 CC women diagnosed in 2000–2007 and followed-up to December 2008. Age-standardised 5-year relative survival (RS) and the excess risks of cancer death in the 5 years after diagnosi…

MorphologyAdultMaleStage at diagnosiSurvivalAdolescentSocio-culturaleUterine Cervical NeoplasmsDiseaseSettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineMedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unionSurvival ratePopulation-based studymedia_commonAgedRetrospective StudiesCervical cancerAged 80 and overCervical cancer Europe Morphology Population-based study Stage at diagnosis Survival030219 obstetrics & reproductive medicineRelative survivalbusiness.industryAbsolute risk reductionObstetrics and GynecologyRetrospective cohort studyStage at diagnosisGeneral MedicineMiddle Agedmedicine.diseaseEuropeEastern europeanSurvival Rate030220 oncology & carcinogenesisCervical cancerFemalebusinessDemographyArchives of gynecology and obstetricsReferences
researchProduct

Differences in the management and survival of metastatic colorectal cancer in Europe. A population-based study

2020

The management regarding metastatic colorectal cancer throughout Europe is not well known.To draw a European comparison of the management and prognosis of metastatic colorectal cancers.Factors associated with chemotherapy administration were identified through logistic regressions. Net survival was estimated and crude probabilities of death related to cancer and other causes using a flexible cumulative hazard model.Among the 13 227 patients with colorectal cancer diagnosed between 2010 and 2013 in cancer registries from 10 European countries, 3140 were metastatic. 62% of metastatic patients received chemotherapy. Compared to Spain, the related adjusted odds ratios ranged from 0.7 to 4.0 (P0…

MaleOncologymedicine.medical_specialtySurvivalColorectal cancerPopulationAntineoplastic AgentsLogistic regressionMetastasisMetastasis03 medical and health sciences0302 clinical medicineInternal medicineHealth caremedicineHumansRegistriesNeoplasm MetastasisDisease management (health)educationAgedRetrospective StudiesAged 80 and overeducation.field_of_studyHepatologybusiness.industryGastroenterologyDisease ManagementCancerOdds ratioMiddle Agedmedicine.diseaseColorectal cancerEurope030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologyColorectal NeoplasmsbusinessDigestive and Liver Disease
researchProduct

Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)

2016

Abstract Objective Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15–99years) diagnosed with ovarian cancer during 1995–2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-sp…

0301 basic medicineOncologySettore MED/42 - Igiene Generale E Applicata0302 clinical medicinemorphology80 and overStage (cooking)Aged 80 and overOvarian Neoplasmseducation.field_of_studyepidemiology; histology; morphology; ovarian cancer; stage; survival; Adolescent; Adult; Aged; Aged 80 and over; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Oncology; Obstetrics and GynecologyObstetrics and Gynecologyepidemiology; histology; morphology; ovarian cancer; stage; survivalMiddle AgedTransitional cell carcinomaovarian cancerOncology030220 oncology & carcinogenesisClear cell carcinomaepidemiologyFemaleHumanAdultmedicine.medical_specialtyAdolescentPopulationSocio-culturalesurvivalArticlehistology03 medical and health sciencesInternal medicinemedicineHumansovarian cancer epidemiology survival stage morphology histologyeducationepidemiology ; histology ; morphology ; ovarian cancer ; stage ; survivalCancer stagingAgedNeoplasm StagingGynecologybusiness.industryOvarian NeoplasmCancermedicine.diseasestageCancer registry030104 developmental biologyOvarian cancerbusiness
researchProduct

Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual…

2017

BACKGROUND: Global inequalities in access to health care are reflected in differences in cancer survival. The CONCORD programme was designed to assess worldwide differences and trends in population-based cancer survival. In this population-based study, we aimed to estimate survival inequalities globally for several subtypes of childhood leukaemia. METHODS: Cancer registries participating in CONCORD were asked to submit tumour registrations for all children aged 0-14 years who were diagnosed with leukaemia between Jan 1, 1995, and Dec 31, 2009, and followed up until Dec 31, 2009. Haematological malignancies were defined by morphology codes in the International Classification of Diseases for …

childhood leukaemiaCancer registrieleukemiacancerchildhood cancerSocio-culturaleHematologySettore MED/42 - Igiene Generale E ApplicataHematology childhood leukaemia cancer survivalcancer survival
researchProduct